FCCC LOGO Faculty Publications
Mason WS , Litwin S , Jilbert AR
Immune selection during chronic hepadnavirus infection
Hepatology International. 2008 Mar;2(1) :3-16
PMID: ISI:000257814000002   
Back to previous list
Abstract
Purpose Late-stage outcomes of chronic hepatitis B virus (HBV) infection, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) result from persistent liver injury mediated by HBV antigen specific cytotoxic T lymphocytes (CTLs). Two other outcomes that often accompany chronic infection, the emergence of mutant viruses, including HBe-antigen negative (HBeAg (-)) HBV, and a reduction over time in the fraction of hepatocytes productively infected with HBV, may also result from persistent immune attack by antiviral CTLs. To gain insights into how these latter changes take place, we employed computer simulations of the chronically infected liver. Methods Computational programs were used to model the emergence of both virus-free hepatocytes and mutant strains of HBV. Results The computer modeling predicted that if cell-to-cell spread of virus is an efficient process during chronic infections, an HBV mutant that replicated significantly more efficiently than the wild type would emerge as the prevalent virus in a few years, much more rapidly than observed, while a mutant that replicated with the same or lower efficiency would fail to emerge. Thus, either cell-to-cell spread is inefficient or mutants do not replicate appreciably more efficiently than wild type. In contrast, with immune selection and a higher rate of killing of hepatocytes infected with wild-type virus, emergence of mutant virus can be explained without the need for a higher replication rate. Immune selection could also explain the emergence of virus-free hepatocytes that are unable to support HBV infection, since they should have a lower turnover rate than infected hepatocytes.
Notes
ISI Document Delivery No.: 328QX Times Cited: 0 Cited Reference Count: 62 Cited References: BANNASCH P, 2003, TOXICOL PATHOL, V31, P134 BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94 BILL CA, 2004, P NATL ACAD SCI USA, V101, P11135 CHEN HS, 1992, J VIROL, V66, P5682 CHEN MT, 2004, P NATL ACAD SCI USA, V101, P14913 CHU CM, 1997, J CLIN MICROBIOL, V35, P102 DANDRI M, 2000, HEPATOLOGY, V32, P139 EVANS AA, 1998, CANCER EPIDEM BIOMAR, V7, P559 FELD JJ, 2006, SEMIN LIVER DIS, V26, P116 GARCIA PD, 1988, J CELL BIOL, V106, P1093 GONG SS, 1995, J VIROL, V69, P8102 GONG SS, 1996, J VIROL, V70, P2000 GONG SS, 1999, J VIROL, V73, P1492 GOVINDARAJAN S, 1990, ARCH PATHOL LAB MED, V114, P1042 GOWANS EJ, 1985, INTERVIROLOGY, V24, P220 GOWANS EJ, 1985, J CLIN PATHOL, V38, P393 HADZIYANNIS SJ, 2006, SEMIN LIVER DIS, V26, P130 HIROHASHI S, 1982, J NATL CANCER I, V69, P565 HSU HC, 1988, CANCER, V62, P915 JACOB JR, 1997, HEPATOLOGY, V26, P1607 JILBERT AR, 1989, THESIS U ADELAIDE AD JILBERT AR, 1992, J VIROL, V66, P1377 KAJINO K, 1994, J VIROL, V68, P5792 KANN M, 2004, METH MOLEC MED, V95, P213 KANN M, 2007, WORLD J GASTROENTERO, V13, P39 KENNEDY S, 1995, HEPATOLOGY, V22, P160 KOJIMA M, 1977, GASTROENTEROLOGY, V73, P664 LAMOTHE F, 1976, GASTROENTEROLOGY, V71, P102 LENHOFF RJ, 1998, VIROLOGY, V251, P85 LENHOFF RJ, 1999, HEPATOLOGY, V29, P563 LI YH, 2002, J HEPATOL, V37, P478 LITWIN S, 2005, J CLIN VIROL S1, V34, S96 MASON WS, 1983, VIROLOGY, V131, P375 MASON WS, 2005, P NATL ACAD SCI USA, V102, P1139 MURRAY JM, 2005, P NATL ACAD SCI USA, V102, P17780 NAYAK NC, 1977, INT J CANCER, V20, P643 NEWBOLD JE, 1995, J VIROL, V69, P3350 NOWAK MA, 1996, P NATL ACAD SCI USA, V93, P4398 OMATA M, 1987, GASTROENTEROLOGY, V92, P192 OU JH, 1989, J VIROL, V63, P5238 PROTZER U, 1999, P NATL ACAD SCI USA, V96, P10818 PULT I, 2001, J VIROL, V75, P9623 RADAEVA S, 2000, J HEPATOL, V33, P580 RAY MB, 1976, GASTROENTEROLOGY, V71, P462 REHERMANN B, 1995, J CLIN INVEST, V96, P1527 SCHLICHT HJ, 1987, J VIROL, V61, P3701 SEEGER C, 2006, FIELDS VIROLOGY, P2977 SUMMERS J, 1991, J VIROL, V65, P1310 SUMMERS J, 2003, P NATL ACAD SCI USA, V100, P11652 SUZUKI K, 1985, CANCER, V56, P321 TAGAWA M, 1986, VIROLOGY, V152, P477 WIELAND SF, 2004, P NATL ACAD SCI USA, V101, P2129 XU CX, 2007, VIROLOGY, V359, P283 YANG D, 1993, CANCER RES, V53, P2020 YANG WG, 1995, J VIROL, V69, P4029 YANG WG, 1998, J VIROL, V72, P8710 YANG WG, 1999, J VIROL, V73, P9710 YEH CT, 2006, J MED VIROL, V78, P906 ZHANG YY, 1999, J VIROL, V73, P3616 ZHANG YY, 2000, J VIROL, V74, P5257 ZHANG YZ, 2003, P NATL ACAD SCI USA, V100, P12372 ZHU Y, 2001, J VIROL, V75, P311 Mason, William S. Litwin, Sam Jilbert, Allison R. SPRINGER; 233 SPRING ST, NEW YORK, NY 10013 USA